These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

27 related articles for article (PubMed ID: 3663879)

  • 1. Extended-release formulations for the treatment of epilepsy.
    Bialer M
    CNS Drugs; 2007; 21(9):765-74. PubMed ID: 17696575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel drug delivery systems. An overview of their impact on clinical pharmacokinetic studies.
    Banerjee PS; Robinson JR
    Clin Pharmacokinet; 1991 Jan; 20(1):1-14. PubMed ID: 2029799
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetic comparison of a once-daily and twice-daily theophylline delivery system.
    González MA; Kisicki J; Straughn AB
    Clin Ther; 1994; 16(4):686-92. PubMed ID: 7982257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl.
    Hurwitz A; Karim A; Burns TS
    J Clin Pharmacol; 1987 Nov; 27(11):855-61. PubMed ID: 3429692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacokinetic analysis of a novel sustained-release dosage form of theophylline in humans.
    Raz I; Bialer M; Salame K; Bar-On H
    Eur J Clin Pharmacol; 1984; 26(3):401-3. PubMed ID: 6734702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rise and fall of serum theophylline concentration: a comparison of sustained-release formulations in volunteers with rapid theophylline clearance.
    Mucklow JC; Kuhn S
    Br J Clin Pharmacol; 1985 Dec; 20(6):589-96. PubMed ID: 4091990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Release and absorption characteristics of novel theophylline sustained-release formulations: in vitro-in vivo correlation.
    Hussein Z; Friedman M
    Pharm Res; 1990 Nov; 7(11):1167-71. PubMed ID: 2293217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic analysis of sustained-release dosage forms of theophylline in humans: comparison of single and multiple dose studies.
    Hussein Z; Bialer M; Friedman M; Raz I
    Biopharm Drug Dispos; 1987; 8(5):427-35. PubMed ID: 3663879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.
    Hendeles L; Iafrate RP; Weinberger M
    Clin Pharmacokinet; 1984; 9(2):95-135. PubMed ID: 6370542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained release theophylline preparations. Practical recommendations for prescribing and therapeutic drug monitoring.
    Glynn-Barnhart A; Hill M; Szefler SJ
    Drugs; 1988 Jun; 35(6):711-26. PubMed ID: 3048977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Theophylline steady-state pharmacokinetics: recent concepts and their application in chronotherapy of reactive airway diseases.
    Steinijans VW; Trautmann H; Johnson E; Beier W
    Chronobiol Int; 1987; 4(3):331-47. PubMed ID: 3315264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Food interactions with sustained-release theophylline preparations. A review.
    Jonkman JH
    Clin Pharmacokinet; 1989 Mar; 16(3):162-79. PubMed ID: 2656048
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.